- **Bio-Data of Professor Raghuram Rao Akkinepally**

Name	**Dr. RAGHURAM RAO AKKINEPALLY**
Date of Birth	**15-06-1960** [Fifteenth June Nineteen Sixty]
Address	Professor of Pharmacy, University College of Pharmaceutical Sciences, Kakatiya University, Warangal Telangana State – 506 009
Contact Numbers	Phone: 0870-244 6259 / 256 7472
	Mobile: 8790 432 456
E-mail	raghumed@kakatiya.ac.in

- Educational Qualification:

Qualification	%Achieved	Year	University	Subject / Topic of Specialization
Post-doctorate	Not Applicable	1991-93	Westfalische Wilhelms Universitat, Muenster, Germany	Pharmaceutical Chemistry
Ph. D.	Not Applicable	1986-91	Kakatiya University	Pharmaceutical Chemistry
Postgraduation [M. Pharm.]	75	1982-84	Andhra University	Pharmaceutical Chemistry
Graduation [B. Pharm.]	73	1976-80	Kakatiya University	Pharmacy

- Present Position:

Present Position Held	Organization	From (Date)	Total Experience
Professor	Kakatiya University and Panjab University	01/04/2011- Till Date 01/03/2006- 31/03/2011	10 Years and 06 months

- Academic Experience / Service Details:

Post	Organization	Duration		Experience Years & Months
		From	To	
Vice-Chancellor	-	-	-	-
Professor	Kakatiya University	01/04/2011	Till Date	5 Years and 4 months
Professor	Panjab University	03/03/2005	31/03/2011	5 Years and 1 month
Associate Professor	Kakatiya University	01-03-1996	02-03-2006	10 Years
Assistant Professor	Kakatiya University	31-03-1991	01-03-1996	04 years 11 months
Lecturer	Kakatiya University	1-07-1985	30-03-1991	5 Years 10 months

- International Academic Exposures, if any:

Position	Organization & Country	Duration	
		From	To
Visiting Professor	University of Minnesota, USA	01/06/2016	11/06/2016
Visiting Scientist	University of Bonn, Germany	02/01/2003	31/01/2003
Visiting Scientist	University of Bonn, Germany	02/07/2002	01/10/2002
Head, Department of Pharmacy	Ministry of Health (MoH), Kingdom of Saudi Arabia	01/10/1999	01/06/2001
DAAD Fellow	Westfalische Wilhelms Universitat, Muenster, Germany	01/06/1991	10/08/1993

- Administrative Posts held:

Sl. No.	Post	Organization	Duration	
			From	To
1	Dean, Faculty of Pharmaceutical Sciences	Kakatiya University	06/02/2012	10/03/2014
2	Director, Central Animal House	Panjab University	20/11/2010	31/03/2011
3	Director, Ph. D. Entrance Cell	Panjab University	01/07/2009	10/12/2010
4	Director, Consultancy Cell	Kakatiya University	10/03/2003	09/03/2005

5	Principal & Head, University College of Pharm. Sciences	Kakatiya University	06/11/2002	10/11/2004
6	Head, Department of Pharmacy, College of Health, Al-Rass	Ministry of Health (MoH), Kingdom of Saudi Arabia	01/10/1999	01/06/2001
7	Warden, Pharmacy Hostel	Kakatiya University	02/03/1989	30/05/1991
8	Programme officer, NSS Unit	Kakatiya University	01/06/1987	01/03/1989
9	Production Officer	Kigo Pharma Pvt Ltd, Hyderabad	01/12/1980	04/08/1982

- Research Projects Executed by the Applicant

	Completed	Under Process
National	010	01
International	01	-

- No, of Ph. D.s Successfully Guided

	Awarded	Under Process
Ph. D.	16	07 (2 submitted)

- Area of Specialization:

Areas of specialization include design and synthesis of adenosine receptor modulators as antiasthma agents, aromatase inhibitors (breast cancer therapy) [**patent commercialized and KU &PU received Royalty Payments**], prodrug and targeted delivery using ADEPT approaches for cancer. For industrial consultancy applications, worked for impurity profiling and cocrystallization for improved physico-chemical profile of poorly soluble drugs.
We could establish regular working / collaboration with different reputed institutes like: University of Bonn (DST- DAAD project); Saarlands University (aromatase inhibitors); University of Wurzburg (adenosine antagonism); King's College, London (aromatase), National Cancer Institute, Bethesda, USA (anticancer screening) and University of Minnesota (USA) for cocrystal research.

- Scholarships / Awards / Memberships / Fellowships etc. of Academic Societies:

Sr. No.	Name of the Award / Fellowship	Year	Awarded by
1	Best Teacher Award	2016	Telangana State Government
2	Fellow	2016	Telangan State Academy of Science
3	Member	2016	American Chemical Society
4	Dr Manjushree Pal Memorial Award for Best Pharmaceutical Scientist of the Year	2010	Association of Pharmaceutical Teachers of India (APTI)
5	DAAD Fellowship (Senior)	2002	DAAD, Germany
6	Career Award for Young Teacher	1995	AICTE
7	DAAD Fellow	1991	DAAD, Germany (UGC Quota)
8	Life Member	1988	Indian Pharmaceutical Association, APTI, Pharma Alumni Assn,
9	Kondaveeti Mallayya Sastry Memorial Gold Medal for First Rank (M. Pharm)	1984	Andhra University
10	Silver Jubilee Award (I Rank M Pharm I Yr)	1984	Andhra University

Projects completed / Ongoing:

Project Title	**Funding Agency**	**Funds Sanctioned(Rs)**
1.Synthesis and Evaluation of New Heteryl Ethers as Potential H1-Antihistaminics (1986- 89)	CSIR (SRF)	3,20,000
2. Synthesis and Evaluation of New Heteryl Esers as Potential H1-Antihistaminics (1989-91)	UGC(MRP)	50,000
3. Synthesis and Evaluation of New Imidazoquinazolines as Potential bronchodilators (1995-98)	AICTE(under CAREER AWARD)	3,60,000
Design and Development of Novel PDE inhibitors as Potential bronchodilators (1998-2000)	AICTE (R&D P)	8,40,000
Synthesis and Evaluation of New A2B Adenosine receptor antagonists as antiasthmatic agents (2003-2005)	DST (under DST-DAAD)	2,90,000
Studies on synthesis and separation of optically pure drugs and their impurity profiles (2004-06)	AICTE (under MODROBS)	15,00,000
Design and development of novel heterofused- pyrimidines as possible antiasthmatic agents with selective adenosine antagonism (2007-2010)	CSIR	6,80,000

Studies on synthesis and bioevaluation of novel fluorinated imidazo [1, 2 – c] quinazolines, quinolines and isoquinolines and fused indoles as antiinflammatory agents (2007-09)	AICTE	10,00,000
Design and synthesis of novel fluorinated derivatives as adenosine receptor antagonists (2007-10)	UGC [Major Research Project]	8,20,000
Design and development of novel molecules of therapeutic interest (2009-12)	M/s. Senative Therapeutics Ltd	12,60,000
Enhanced solubulization using co-crystal strategy of some selected drug molecules (2014-2016)	M/s. Aizant Pharma (P) Ltd, Hyderabad	4,00,000 (in progress)
Design and development of multi-target directed tacrine analogues for use in the treatment of alzheimer's disease	UGC [Major Research Project]	14,80,000 (in progress)

Number of Ph.Ds guided (completed/in progress) Year-wise with thesis names

S.No.	Name of Student	Title of the Thesis
1	Rajesh. H Bahekar (1997-2000	Synthesis and Evaluation New Bronchodilators
2	M. Raghu Prasad (2000-03)	Synthesis and Evaluation New Antiasthmatic Agents
3	K.S. Rajan (2001-04)	Synthesis and Evaluation New Adenosine Antagonists as New Antiasthmatic Agents
4	M. Bhagawan Raju (2001-05)	Synthesis and Evaluation of New H1-Antihistaminic Agents
5	D. Hari Krishna (2003-06)	Design on Prodrugs for Solid Tumor Therapy using ADEPT Strategy
6	S. Meena (2003-06)	Impurity Profiles of Nonsteroidal Antiinflammatory Agents
7	J. Narasimha Murthy (2004-08)	Design and Synthesis of Nonsteroidal Aromatase Inhibitors for Breast cancer Therapy
8	P. Mani Chandrika (2004-08)	Synthesis and Evaluation of New Quinazolinones as H1-Antihistaminic Agents
9	B. Shireesha (2004-08)	Design, Synthesis & Evaluation of novel heterofused thiophenes as possible adenosine receptor antagonists
10	B. Lakshmi Narayana (2009-12)	Design, Synthesis of novel Non-steroidal aromatase inhibitors for breast cancer therapy
11	C.Bala Kumar (2008-12)	Design, Synthesis & Evaluation of novel heterofused derivatives of adenosine receptor antagonists
12	Pran Kishore Deb (2009-13)	Design, synthesis and evaluation of Antiasthmatic activity of some heterofused pyrimidines
13	Upendra K. Jain (2009-12)	Design, synthesis and evaluation of new boronic chalcones as antitumor agents
14	K Venkata Rao (2009-13)	Design & Synthesis of new adenosine kinase Inhibitors
15	Rajwinder Kaur (2009-14)	Design, Synthesis & Evaluation of novel hetero-fused derivatives of A2b-adenosine receptor antagonists
16	Raghuram Reddy Adidala (2007-	Design on Prodrugs for Solid Tumor Therapy using

	14)	ADEPT and PMT Strategies
17	M. Narender (2011-) **Submitted**	Target based design, synthesis and evaluation of new DHFR inhibitors as antimalarials
18	Bh. Santosh Jaswanth Kumar (2012-	Preparation and characterization of cocrystals of antitumor agents to enhance solubility and bioavailability
19	A. Ramesh (2012-	Design, synthesis and screening of some new pyridine derivatives
20	Prabhakar A. S. (2012- **Submitted**	Synthesis of methylenedioxy containing compounds for potent pharmacological actions
21	N. Chandana (2014-	Utilization of clinical and biochemical markers in the diagnosis and malfunctional intervention in cardiovascular disease- a follow up study
22	E. Shivarani (2015-	Improvization of physicochemical properties of some selected drugs using co-crystallization techniques
23	M. Srujana (2015-	Synthesis, characterization and evaluation of aza analogues of flavones and flavanones as aromatase inhibitors

Number of publications (national/international & impact factor details:
Year wise (list titles, name of journal and number of citations):
Total: 81 [National: 19; International: 62]

International (Original work)

- *Synthesis, In Vitro Antimycobacterial Evaluation and Docking Studies of Some New 5,6,7,8-Tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one Schiff Bases,* Narender Malothu et al., Bioorg.& Med. Chem. Lett. 2016, 26, 836

- *Enhanced Solubility Studies of Eprosartan Mesylate By Cocrystallization And Their Characterization Using Dsc And Spectroscopic Methods*. Jaswanth S. Bhandaru et al., Cryst. Growth Des., 2015, 15 (3), 1173–1179. (Impact factor: 4.891; Citations: 0)

- *Basic Ionic Liquid [bmIm]OH–Mediated Gewald Reaction as Green Protocol for the Synthesis of 2-Aminothiophenes*. Kaki, V.R. etal. Synth. Commun. 2015, 45, 119. (Impact factor: 0.984; Citations: 1)

- *New Malabaricane type triterpenes from Ailanthus malabarica.* Achanta, P.S.et al, Fitoterapia. 2015, 100, 166. (Impact factor: 2.216; Citations:)

- *Synthesis, anti-inflammatory evaluation, and docking studies of some new thiazole derivatives.* Deb, P.K et al., Med. Chem. Res. 2014, 23, 2780. (Impact factor: 1.612; Citations: 0)

- *Facile Methods for the Synthesis of 5-Aryl and 5-Iodo Pyrrolo[2,3-d]pyrimidines*, K. Venkata Rao et al., J. Heterocycl. Chem. 2014, 51, 380-383. (Impact factor: 0.797; Citations: 8)

- *Design and Development of Halogenated Chalcone Derivatives as Potential Anticancer agents.* Jain, U.K; et al., Trop. J. Pharm. Res. 2014, 13, 73. (Impact factor: 0.820; Citations: 2)

- *Antiinflammatory Evaluation and Docking Studies of Some New Thienopyrimidines.* Deb, P.K et al., Asian J. Chem. 2013, 25, 10583. (Impact factor: 0.355; Citations: 1)

- *Synthesis of novel pyrido[3,2-e][1,2,4]triazolo[1,5-c]-pyrimidine derivatives: Potent and selective adenosine A3 receptor antagonists.* Veeraswamy, B.et al., Archiv der Pharmazie. 2013, 346, 699. (Impact factor: 1.396; Citations: 3)

- *Pharmacophore Modeling and QSAR Analysis of Novel β-carboline Derivatives as Antitumor Agents.* Chourasiya, R.K.et al., Lett. Drug Des. Disc. 2013, 10, 572. (Impact factor: 0.961; Citations: 2)

- *QSAR and docking studies of novel b-carboline derivatives as anticancer agents.* Chourasiya, R.K.et al., Med Chem Res 2013, 22, 2991. (Impact factor: 1.612; Citations: 1)

- *Transesterification of trimethylorthoacetate: an efficient protocol for the synthesis of 4-alkoxy-2-aminothiophene-3-carbonitrile.* Rao, K.V. et al, Tet. Lett. 2013, 54, 1274. (Impact factor: 2.391; Citations: 1)

- *Molecular docking and receptor-specific 3D-QSAR studies of acetylcholinesterase inhibitors.* Pran Kishore, D. et al., A. Molecular docking and receptor specific Mol. Divers. 2012, 16, 803. (Impact factor: 2.544; Citations: 6)

- *Design and synthesis of triphenyl-1H-pyrazole derivatives as anticancer agents.* Jain, U.K et al., Int. J. Pharm. Pharm. Sci. 2012, 4, 600. (Impact factor: Not available; Citations: 0)

- *An improved synthesis of lysosomal activated mustard prodrug for tumor specific activation and its cytotoxic evaluation.* Raghuram Reddy, A.et al., Drug Dev. Ind. Pharm. 2012, 38, 1047. (Impact factor: 2.006; Citations: 1)

- *Pharmacophore based 3D-QSAR modeling and in silico study of biphenyl derivatives as nonsteroidal aromatase inhibitors in JEG-3 cell lines.* Narayana, B.L. et al., Med. Chem. 2013, 9, 974. (Impact factor: 1.387; Citations: 0)

- *Synthesis, evaluation of 6,8-dibromo-2-aryl-2,3-dihydroquinolin-4(1H)-ones in MCF-7 (breast cancer) cell lines and their docking studies.* Lakshmi Narayana, B. et al., Med. Chem. Res. 2012, 21, 1741. (Impact factor: 1.612; Citations: 7)

- *Molecular modeling evaluation of non-steroidal aromatase inhibitors.* Lakshmi Narayana, B.et al., Chem. Biol. Drug. Des. 2012, 79, 674. (Impact factor: 2.507; Citations: 12)

- *QSAR of adenosine receptor antagonists: Exploring physicochemical requirements for binding of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives with human adenosine A3 receptor subtype.* Pran Kishore, D. et al., Bioorg. Med. Chem. Lett. 2011, 21, 818. (Impact factor: 2.331; Citations: 15)

- *A facile microwave-assisted synthesis of 8,9-cycloalkathieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-ones.* Kaur, R. et al., J. Chem. Sci. 2010, 123, 69. (Impact factor: 1.224; Citations: 4)

- *Synthesis, anti-inflammatory evaluation and docking studies of some new fluorinated fused quinazolines.* Balakumar, C. et al., Eur. J. Med. Chem., 2010, 45, 4904. (Impact factor: 3.432; Citations: 45)

- *N- Substituted quinazolin-2,4-diones as adenosine receptor ligands.* Shireesha, B. et al., Intl. J. Pharm. Sci. Nanotech. 2010, 3, 1015. (Impact factor: Not available; Citations: 0)

- *Synthesis and theoretical studies on energetics of novel N- and O- perfluoroalkyl triazole tagged thienopyrimidines - their potential as adenosine receptor ligands.* Shireesha, B. et al., Eur. J. Med. Chem. 2010, 45, 1739. (Impact factor: 3.432; Citations: 19)

- *Click chemistry: studies on the synthesis of novel fluorous tagged triazol-4-yl substituted quinazoline derivatives and their biological evaluation – theoretical and experimental validation.* Mani Chandrika, P. et al. Eur. J. Med. Chem. 2010, 45, 78. (Impact factor: 3.432; Citations: 33)

- *Synthesis of new 2-substituted pyrido[2,3-d]pyrimidin-4(1H)-ones and their antibacterial activity.* Lakshmi Narayana, B. et al., Eur. J. Med. Chem. 2009, 44, 1369. (Impact factor: 3.432; Citations: 39)

- *Synthesis and bronchodilator studies of some novel 6-alkyl/aryl-1,2,4-triazino[4,3-c]quinazolines.* Rajan, S. K. et al., Open Med. Chem. J. 2008, 2, 101. (Impact factor: Not available; Citations: 3)

- *Synthesis and antibacterial activity of new series of 2,3,5,7-substituted- pyrido[2,3-d]pyrimidin-4-one derivatives.* Lakshmi Narayana, B. et al., Chem. Pharm. Bull. 2008, 56, 1342. (Impact factor: 1.507; Citations: 9)

- *Design, synthesis and H1-antihistaminic activity of thieno[2,3-d]pyrimidines.* Shireesha, B. et al. Intern. J. Pharm. Sci. & Nanotech. 2008, 1, 136. (Impact factor: Not available; Citations: 7)

- *Synthesis of novel 4,6-disubstituted quinazoline derivatives, their antiinflammatory and anticancer activity against U937 leukemia cell lines.* Mani Chandrika, P. et al., Eur. J. Med. Chem. 2008, 43, 846. (Impact factor: 3.432; Citations: 113)

- *Safety, pharmacokinetics and biodistribution studies of a β -galactoside prodrug of doxorubicin for improvement of tumor selective chemotherapy.* Harikrishna, D. et al., Drug Dev. Ind. Pharm. 2008, 34, 789. (Impact factor: 2.006; Citations: 14)

- *Design, synthesis and adenosine receptor binding studies of some novel triazolothienopyrimidines.* Raghu Prasad, M. et al., Eur. J. Med. Chem. 2008, 43, 614. (Impact factor: 3.432; Citations: 19)

- *QSAR study on pyrimidine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors – a mixed approach.* Vasanthnathan, P. et al., Med. Chem. 2007, 3, 227. (Impact factor: 1.387; Citations: 5)

- *β- Galactoside prodrugs of doxorubicin for application in antibody directed enzyme prodrug therapy / prodrug monotherapy.* Harikrishna, D. et al., Arch. Pharm. Res. 2007, 30, 723. (Impact factor: 1.751; Citations: 24)

- *Development of reversed phase liquid chromatographic separation method for process related impurities of celecoxib by dynamically coating the column with hexamethyl disilazane.* Rao, R. N. et al., Anal. Sci., 2006, 22, 1257. (Impact factor: 1.403; Citations: 5)

- *Development and validation of a reversed-phase liquid chromatographic method for separation and simultaneous determination of COX-2 inhibitors in pharmaceuticals and its application to biological Fluids.* Meena, S. Et al., A. Biomed. Chromatogr. 2005, 19, 362. (Impact factor: 1.662; Citations: 38)

- *Active site acidic residues and structural analysis of human aromatase: molecular modeling study based on mammalian CYP2C5.* Narashima Murthy, J. et al., J. Comput. Aided Mol. Des. 2005, 2, 857. (Impact factor: 2.782; Citations: 2)

- *Synthesis and antiinflammatory activity of alkyl / arylidene-2-aminobenzothiazoles and 1-benzothiazol-2-yl-3-chloro-4-substituted-azetidin-2-ones.* Khedekar, P. B. et al., Arzneim.- Forsch. / Drug Res. 2003, 53, 640. (Impact factor: 0.632; Citations: 15)

- *1,2,4-Triazolo[1,5-c]quinazolin-2(3)-ones: a one-pot synthesis.* Rajan, K. S. et al, J. Chem. Res. 2002, 490-492. (Impact factor: 0.622; Citations: 1)

- *Synthesis and anticonvulsant activity of 3-(6-substituted-benzothiazol-2-yl)-6-phenyl[1,3]oxazin-2-thiones.* Chopade, R. S. et al., Arch. Pharm. Pharm. Med. Chem. (Weinheim, Ger.) 2002, 335, 381. (Impact factor: 0.624; Citations: 31)

- *A facile route for the synthesis of thienopyrimidines.* Raghu Prasad, M. et al., J. Chem. Res. 2002, (S), 5 and J. Chem. Res. (M), 0149. (Impact factor: 0.622; Citations: 0)

- *Microwave assisted synthesis of novel 5-substituted 2,3-dihydroimidazo[1,2-c] thieno[3.2-e]pyrimidines.* Prasad, M. R. et al., Synthesis, 2001, 14, 2119. (Impact factor: 1.985; Citations: 16)

- *Synthesis, Evaluation and Structure-Activity Relationships of 5-Alkyl-2,3-dihydroimidazo[1,2-c]quinazoline, 2,3-Dihydroimidazo[1,2-c]quinazolin-5(6H)-thiones and their Oxo-analogues as New Potential Bronchodilators.* Bahekar, R. H. and Raghu Ram Rao, A. Arzneim.-Forsch. / Drug Res. 2001, 51, 282. (Impact factor: 0.632; Citations: 18)

- *Bronchodilation and structure activity relationship studies on new 6-substituted benzimidazo[1,2-c] quinazolines.* Raghu Ram Rao, A. and Bahekar, R. H. Arzneim.-Forsch. / Drug Res. 2000, 50, 712. (Impact factor: 0.632; Citations: 12)

- *Synthesis and analgesic activity of some novel 2-substituted 1,3,4-thiadiazolo[2,3-b] disubstituted / tetrasubstituted thieno[3,2-e] pyrimidin-5(4H)-ones.* Prasad, M. R. et al., Arzneim.-Forsch. / Drug Res. 2000, 50, 904. (Impact factor: 0.632; Citations: 13)

- *A facile method with improved yields in the synthesis of 6-arylpyrido[2',3':4,5] pyrimido[1,2-a] quinazolines.* Suma, G.et al., Org. Prep. Proced. Internl. 2000, 32, 99. (Impact factor: 1.015; Citations: 6)

- *Photochemical studies part: 66. Solid state photochemical investigations of methyl prednisolone, prednisolone and triamcinolone acetonide.* Reisch, J. et al., Acta Pharm. Turcica. 1995, 37, 13. (Impact factor: 0.604; Citations: 0)

- *Photochemical studies part: 71. photostability studies in solid state and crystal structure of mifepristone.* Reisch, J. et al. Arch. Pharm. (Weinheim, Ger.) 1994, 327, 809. (Impact factor: 1.7; Citations: 4)

- *Synthesis and evaluation of N- heteryl β - alkoxyethyloxy and β-(N,N-dialkylamino)-ethyloxy acetamides as possible H1-antihistaminics.* Rao, A.R.R. and Reddy, V. M. J. Pharm. Sci. 1994, 83, 953. (Impact factor: 3.055; Citations: 6)

- *Photochemical studies part: 68. dimerizaton of levonorgestrel in ultravoilet light irradiation.* Reisch, J. Et al., Pharm. Acta Helv. 1994, 69, 97. (Impact factor: Not available; Citations: 10)

- *Acetylenic chemistry part: 32. alkinylation and cyclic rearrangement of theophylline with unsaturated alcohols by Mitsunobu reaction.* Reisch, J. et al., Monatsh. Chem. 1994, 125, 79. (Impact factor: 1.347; Citations: 2)

- *Photostability studies of ouabain, α-acetyldigoxin and digoxin in solid state.* Reisch, J. et al., Pharm. Acta Helv. 1994, 69, 47. (Impact factor: Not available; Citations: 3)

- *Acetylenic chemistry part: 27. One-pot synthesis of 1,3-dialkylated derivatives of quinazolinone and its aza-analogue via Mitsunobu reaction.* Reisch, J. et al., Monatsh. Chem. 1993, 124, 1217. (Impact factor: 1.347; Citations: 0)

- *New heteryl acetic and mercaptoacetic esters: synthesis and H1-antihistaminic evaluation.* Rao, A.R.R. and Reddy, V. M. Arzneim. -Forsch. / Drug Res. 1993, 43, 663. (Impact factor: 0.632; Citations: 10)

- *Natural product chemistry part:159. Two methods for the synthesis of azaacronycine as a potential antitumor agent.* Reisch, J. et al., J. Heterocycl. Chem. 1993, 30, 981. (Impact factor: 1.508; Citations: 13)

- *Synthesis and antihistaminic activity of β-alkoxyethyl and β-(N,N-dialkylamino)ethyl) (3-aryl-3,4-dihydro-4-oxoquinazolin-2-yl) methyl ethers.* Rao, A.R.R.; and Reddy, V. M. Pharmazie. 1992, 47, 794. (Impact factor: 1.708; Citations: 0)

Reviews:

- *An overview of the recent developments in analytical methodologies for determination of COX-2 inhibitors in bulk drugs, pharmaceuticals and biological matrices.* Meena, S. et al. J. Pharm. Biomed. Anal. 2005, 39, 349. (Impact factor: 2.829; Citations: 63)

- *Aromatase inhibitors: A new paradigm in breast cancer treatment.* Narshima Murthy, J. et al., Curr. Med. Chem.-Anti Cancer Agents, 2004, 4, 523. (Impact factor: 2.939; Citations: 23)

- *Selective activation of anthracycline prodrugs for use in conjunction with ADEPT.* Harikrishna, D. et al., Drug News and Perspectives, 2003, 16, 309. (Impact factor: Not available; Citations: 10)

- *Recent perspectives in the design of antiasthmatic agents - a review.* Prasad, M. R.; Bahekar, R. H.; Raghu Ram Rao, A. Pharmazie. 2000, 55, 475. (Impact factor: 1.708; Citations: 17)

- *Screening methods for antiasthmatic agents - a review.* Raghu Ram Rao, A. and Prabhakar, M. C. Methods and Findings in Experimental and Clinical Pharmacology. 2000, 22, 191. (Impact factor: Not available; Citations: 1)

- Eleventh Frank Warren Conference. Narayana, B.L. and Rao, A.R. Meeting Report, Curr. Sci. 2010, 99, 1458. (Impact factor: 0.833; Citations: 0)

- Rao, A.R. and Narayana, B.L. Highlights from the AACRs special conference on "*Advances In Breast Cancer Research: Genetics, Biology And Clinical Applications*", held between 13-16, October 2009 at Hyatt regency mission bay spa and marina, San Diego, California, U.S.A. Drugs of the Future. 2010, 35, 77. (Impact factor: Not available; Citations: 0)

National (Original work)

- *Design, Synthesis and Evaluation of New 2,6-Dihydroimidazo[1,2-]Pyrimido[5,4-e]-Pyrimidine-5(3H)-Thiones as Possible Antihistaminic /Antiasthmatic Agents*. Sirisha, K. et al., Indian J. Pharm. Sci. 2014, 76, 519. (Impact factor: 0.338; Citations: 0)
- *New antihistaminic agents-5. Synthesis and H1-antihistaminic evaluation of 3-(N,N-dialkylamino) alkyl derivatives of 2-phenyl-3,4-dihydroquinazolin-4(3H)-ones.* Raju, V. S. K et al., Indian Drugs. 1999, 36, 759. (Impact factor: 0.028; Citations: 5)

- *Synthesis and pharmacological evaluation of 6-aryl benzimidazo[1,2-c]quinazolines as potential bronchodilators.* Raghu Ram Rao, A. and Bahekar, R. H. Indian J. Chem. 1999, 38 B, 434. (Impact factor: 0.489; Citations: 3)

- *Synthesis of benzimidazo[1,2-c]quinazolin-6(5H) –ones and their thio analogues.* Bahekar, R. H. and Raghu Ram Rao, A. Indian J. Heterocycl. Chem. 1999, 8, 225. (Impact factor: 0.244; Citations: 3)

- *Design, microwave-assisted synthesis and in silico docking studies of new 4H-pyrimido[2,1-b]-benzothiazole-2-arylamino-3-cyano-4-ones as possible adenosine A2B receptor antagonists.* Balakumar, C.et al., Indian J. Chem. 2012, 51B, 1105. (Impact factor: 0.489; Citations: 3)

- *Synthesis leading to novel 2,4,6-trisubstituted quinazoline derivatives, their antibacterial and cytotoxic activity against THP-1, HL-60 and A375 cell lines.* Mani Chandrika, P. et al., Indian J. Chem. 2009, 48B, 840. (Impact factor: 0.489; Citations: 27)

- *New antihistaminic agents: part 7- synthesis and H1- antihistaminic evaluation of 3-[N, N-dialkylamino) alkyl]-1, 2, 3, 4-tetrahydro-(1H)-thio-quinazolin-4(3H)-ones and their oxo analogues.* Singh, S. D. et al., Indian J. Pharm. Sci. 2007, 69, 853. (Impact factor: 0.338; Citations: 2)

- *Synthesis of some substituted 2-(4-aminophenyl sulphanilamido) benzothiazoles.* Bhusari, K.P. et al., Indian J. Heterocycl. Chem. 2000, 9, 213. (Impact factor: 0.244; Citations: 0)

- *New bronchodilators–2. synthesis and pharmacological evaluation of 6-alkylbenzimidazo [1,2-c] quinazolines.* Raghu Ram Rao, A. and Bahekar, R.H. Indian J. Pharm. Sci. 2000, 62, 41. (Impact factor: 0.338; Citations: 0)

- *Synthesis of 8-bromo-9-substituted-1,3-benzothiazolo[5,1-b]trizolesand their anthelmintic and antitubercular activity.* Bhusari, K. P. et al., Indian J. Heterocycl. Chem. 2000, 9, 275. (Impact factor: 0.244; Citations: 0)

- *New antihistaminic agents-5. synthesis and H1-antihistaminic evaluation of 3-(N,N-dialkylamino)alkyl derivatives of 6-halo-2-phenyl-3,4-dihydroquinazolin-4(3H)-ones.* Dev Singh, S. et al., Indian J. Chem. 2001, 40B, 813. (Impact factor: 0.489; Citations: 4)

- *Synthesis and antimicrobial activity of 2-substituted aminobenzo-thiazoles.* Bhusari, K. P. et al., Indian J. Heterocycl. Chem. 2001, 10, 231. (Impact factor: 0.244; Citations: 0)

- *Colorimetric method of estimation of doxycycline hydochloride in its formulations.* Kamalapurkar, O. S. and Raghu Ram Rao, A. Eastern Pharmacist. 1986, 29, 201. (Impact factor: Not available; Citations: 0)

- *Synthesis and pharmacological assay of new (6,8-dibromo-2-methyl-3,4-dihydro-4-oxo-quinazolin-3-yl) ethylaminoacetates.* Chandrasekhar, V.et al., Indian Drugs. 1986, 24, 140. (Impact factor: 0.028; Citations: 0)

Reviews:

- *Current Strategies in Breast Cancer Therapy*. Narayana, B.L. et al., Spanacea. 2011, 1. (Impact factor: Not available; Citations: 0)
- *Role of flavonoids in breast cancer therapy: an overview*. Narayana, B.L. et al., Pharmacos. 2010, 37, 29. (Impact factor: Not available; Citations: 0)

- *Quinazoline derivatives with potent antiinflammatory and antiallergic activities – a review.* Chandrika, P.M. et al., Intern. J. Chem. Sci. 2008, 6, 1119. (Impact factor: Not available; Citations: 10)

- *Design of new experiments in Pharmaceutical Instrumental Methods of Analysis – A study on undergraduate students of Pharmacy.* Sirisha, B. et al., Indian J Pharm. Educ. Res. 2008, 42, 199-204 (Impact factor: Not available; Citations: 3)

- *Practice of pharmaceutical care – An essential component of healthcare system.* Raghu Ram Rao, A. and Suresh, P. Indian J. Hosp. Pharm. 2000, 37, 176. (Impact factor: Not available; Citations: 0)